TOP2A and neoplasm: In addition, analysis of tumor samples from several trials81,87,147,150 have reported that deletion of TOP2A may be associated with increased sensitivity and better outcome with anthracycline vs non-anthracycline-based therapy, though this finding is not consistent85.